07 / 03 / 2020
Explicyte was pleased to participate to the AACR Virtual Annual Meeting, last week to get breakthroughs in Immuno-Oncology and to present our posters featuring our capacities / platforms that support drug discovery.
06 / 18 / 2020
Explicyte will be attending the AACR Virtual Annual Meeting 2020 and will present new results from its collaborative work with Domain Therapeutics on the GPCRome modulation in the context of cancer immunotherapy.
06 / 18 / 2020
We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.
06 / 18 / 2020
We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.
06 / 11 / 2020
Take advantage of our upcoming in vitro shuttle session scheduled in early July on our validated M2 macrophage suppression assay, to assess novel immunotherapeutics in time and cost-effective manner.
05 / 14 / 2020
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?
03 / 12 / 2020
Benefit from the upcoming in vitro shuttle session - scheduled in April - on our validated immune cell-mediated killing assay to assess novel immunotherapeutics in time and cost-effective manner.
02 / 11 / 2020
Due to the great success of the registration to our shuttle session - which will be held by mid-march - we are pleased to announce, to all who would still be interested, the availability of newly added seats that can be run on a selection of syngeneic tumor mouse models, ie. EMT6 breast cancer CT26 colon cancer and MCA205 sarcoma.
01 / 29 / 2020
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?
01 / 07 / 2020
Initiate the new year with our next in vitro shuttle session on our validated M2 macrophage suppression assay, which will take place by early February – thereby providing an opportunity to timely and cost-effectively assess novel immunotherapeutics.